BrightGene convertible bond nears early redemption trigger

BrightGene Bio-Medical Technology announced that its "Borui Convertible Bond" is approaching a conditional redemption trigger. As of September 4, 2025, the company's stock price has closed at or above 130% of its current conversion price for ten trading days. If the stock continues to meet this condition for an additional five trading days within the next twenty, the bond's redemption clause will be activated.

The "Borui Convertible Bond" was issued on January 4, 2022, with a total value of 465,000,000 yuan. Its initial conversion price was 35.68 yuan per share, which has been adjusted several times due to equity distributions. The latest adjustment, effective June 23, 2025, set the conversion price at 34.74 yuan per share.

Upon triggering the redemption clause, BrightGene's board of directors will decide whether to redeem all or part of the unconverted bonds at their face value plus accrued interest. The company has advised investors to understand the redemption terms and potential impacts, urging them to monitor subsequent announcements and be aware of investment risks.